| 期刊論文| 1. | 廖建瑜(20110800)。藥品OFF-LABEL USE之管制--以美國與臺灣為例。法學新論，31，37-64。 延伸查詢 | | 2. | 廖建瑜(20111000)。藥品OFF-LABEL USE之管制--以美國與臺灣為例。法學新論，32，45-71。 延伸查詢 | | 3. | 唐淑美、顏上詠、陳祖裕、林正介(20101200)。受試者保護與人體試驗委員會。醫事法學，17(2)，1-12。 延伸查詢 | | 4. | 林誠二(20101000)。人體試驗與雙效理論之探討。法令月刊，61(10)，75-91。 延伸查詢 | | 5. | 陳怡安(20020300)。受試者保護與人體試驗的規範。律師雜誌，270，30-43。 延伸查詢 | | 6. | Darrow, Jonathan J.、Sarpatwari, Ameet、Avorn, Jerry、Kesselheim, Aaron S.(2015)。Practical, Legal, and Ethical Issues in Expanded Access to Investigational Drugs。New England Journal of Medicine，372(3)，279-286。  | | 7. | Maher, Carmen、Lushniak, Boris D.(2009)。Availability of medical countermeasures for bioterrorism events: US legal and regulatory options。Clinical Pharmacology & Therapeutics，85(6)，669-671。 | | 8. | 林欣柔、鄒孟珍(20161000)。成全病人的最後一線生機？--擴大近用試驗中藥品之倫理考量及法律挑戰。萬國法律，209，55-63。 延伸查詢 | | 9. | Krause, Philip R.、Gruber, Marion F.(2020)。Emergency Use Authorization of Covid Vaccines--Safety and Efficacy Follow-up Considerations。The New England Journal of Medicine，383(19)。 | | 10. | Petersen, Michael Bang、Bor, Alexander、Jørgensen, Frederik、Lindholt, Marie Fly(2021)。Transparent communication about negative features of COVID-19 vaccines decreases acceptance but increases trust。Proceedings of the National Academy of Sciences，118(29)。 | | 11. | Kels, Charles G.(2015)。Dispensing Medical Countermeasures: Emergency Use Authorities and Liability Protections。Health Security，13(2)，139-151。 | | 12. | Walsh, Daniel(2021)。COVID-19: A Crisis and an Opportunity to Improve the Emergency Use Authorization Process。Minnesota Journal of Law, Science & Technology，22(2)，169-220。 | | 13. | Mello, Michelle M.、Frakes, Michael D.、Blumenkranz, Erik、Studdert, David M.(2020)。Malpractice Liability and Health Care Quality: A Review。JAMA，323(4)，352-366。 | | 14. | Thomson, Kyle、Nachlis, Herschel(20200831)。Emergency Use Authorizations During the COVID-19 Pandemic: Lessons From Hydroxychloroquine for Vaccine Authorization and Approval。The Journal of the American Medical Association，324(13)，1282-1283。 | | 15. | Jarow, Jonathan P.、Lemery, Steven、Bugin, Kevin、Khozin, Sean、Moscicki, Richard(2016)。Expanded Access of Investigational Drugs: The Experience of the Center of Drug Evaluation and Research Over a 10-Year Period。Therapeutic Innovation & Regulatory Science，50(6)，705-709。 | | 16. | 蘇嘉瑞、張楊全、楊弘仁(20111100)。兼顧「權益保護」與「研究促進」--人體試驗委員會的有效運作與法律規範。臺灣醫界，54(11)，45-50。 延伸查詢 | | 17. | 謝文哲(20210614)。【全台三級警戒】鴻海洽購BNT進法律商談階段 陳時中曝郭台銘開1條件。鏡周刊。 延伸查詢 | | 18. | Annas, George J.(2002)。Bioterrorism, public health, and human rights。Health Affairs，21(6)，94-97。 | | 19. | Binzer, Peggy(2008)。The PREP Act: Liability Protection for Medical Countermeasure Development, Distribution, and Administration。Biosecurity and Bioterrorism，6(4)，293-298。 | | 20. | Blanchard, Janice C.、Haywood, Yolanda、Stein, Bradley D.、Tanielian, Terri L.、Stoto, Michael、Lurie, Nicole(2005)。In Their Own Words: Lessons Learned From Those Exposed to Anthrax。American Journal of Public Health，95(3)，489-495。 | | 21. | Burgessa, David C.、Burgessbc, Margaret A.、Leask, Julie(2006)。The MMR vaccination and autism controversy in United Kingdom 1998-2005: Inevitable community outrage or a failure of risk communication?。Vaccine，24(18)，3921-3928。 | | 22. | Copper, Brian Kurt(2007)。"High and Dry?" The Public Readiness and Emergency Preparedness Act and Liability Protection for Pharmaceutical Manufacturers。Journal of Health Law，40(1)。 | | 23. | Courtney, Brooke、Sherman, Susan、Penn, Matthew(2013)。Federal Legal Preparedness Tools for Facilitating Medical Countermeasure Use during Public Health Emergencies。The Journal of Law, Medicine & Ethics，41(S1)，22-27。 | | 24. | Drew, Liam(2019)。The case for mandatory vaccination。NATURE，575(7784)，S58-S60。 | | 25. | (2020)。COVID vaccine confidence requires radical transparency。NATURE，586(7827)。 | | 26. | Finkelstein, Paige E.(2015)。Expanded Access to Investigational Drugs: What Physicians and the Public Need to Know about FDA and Corporate Processes。AMA Journal of Ethics，17(12)，1142-1146。 | | 27. | Fountzilas, Elena、Said, Rabih、Tsimberidou, Apostolia M.(2018)。Expanded access to investigational drugs: balancing patient safety with potential therapeutic benefits。Expert Opinion on Investigational Drugs，27(2)，155-162。 | | 28. | Freimuth, Vicki S.、Quinn, Sandra C.、Thomas, Stephen B.、Cole, Galen、Zook, Eric、Duncan, Ted(2001)。African American's views on research and the Tuskegee syphilis study。Social Science & Medicine，52(5)，797-808。 | | 29. | Guidry, Jeanine P. D.、Laestadius, Linnea I.、Vraga, Emily K.、Miller, Carrie A.、Perrin, Paul B.、Burton, Candace W.、Ryan, Mark、Fuemmeler, Bernard F.、Carlyle, Kellie E.(2021)。Willingness to get the COVID-19 vaccine with and without emergency use authorization。American Journal of Infection Control，49(2)，137-142。 | | 30. | Hoffman, Sharona、Goodman, Richard A.、Stier, Daniel D.(2009)。Law, Liability, and Public Health Emergencies。Disaster Medicine and Public Health Preparedness，3(2)，117-125。 | | 31. | Jarow, Jonathan P.、Lurie, Peter、Ikenberry, Sarah Crowley、Lemery, Steven(2017)。Overview of FDA's Expanded Access Program for Investigational Drugs。Therapeutic Innovation & Regulatory Science，51(2)，177-179。 | | 32. | Leask, Julie(2002)。Vaccination and risk communication: summary of a workshop, Arlington Virginia, USA, 5-6 October 2000。Journal of Paediatrics and Child Health，38(2)，124-128。 | | 33. | Liu, Brooke Fisher、Quinn, Sandra C.、Egnoto, Michael、Freimuth, Vicki、Boonchaisri, Natalie(2017)。Public Understanding of Medical Countermeasures。Health Security，15(2)，194-206。 | | 34. | Mack, George S.(2009)。Expanded Access Rules Pose Quandary for Drug Developers。Nature Biotechnology，27(10)，871-872。 | | 35. | Marino, Angela(2005)。The Cost of a Countermeasure: The Expansive Liability Protection of the Public Readiness and Emergency Preparedness Act of 2005。University of Florida Journal of Law & Public Policy，20(2)，199-220。 | | 36. | Martinez, William Chanes(2021)。How to Get Away with Immunity: FDA's Emergency Use Authorization Scheme and PREP Act Liability Protection in the Context of COVID-19。Loyola Consumer Law Review，33(1)。 | | 37. | Mayer, Lincoln(2007)。Immunity for Immunizations: Tort Liability, Biodefense, and Bioshield II。Stanford Law Review，59(6)，1753-1790。 | | 38. | McKee, Amy E.、Markon, André O.、Chan-Tack, Kirk M.、Lurie, Peter(2017)。How Often Are Drugs Made Available Under the Food and Drug Administration's Expanded Access Process Approved?。Journal of Clinical Pharmacology，57(S10)，S136-S142。 | | 39. | Moulton, Anthony D.、Gottfried, Richard N.、Goodman, Richard A.、Murphy, Anne M.、Rawson, Raymond D.(2003)。What Is Public Health Legal Preparedness?。The Journal of Law Medicine & Ethics，31(4)，672-683。 | | 40. | Nightingale, Stuart L.、Prasher, Joanna M.、Simonson, Stewart(2007)。Emergency Use Authorization (EUA) to Enable Use of Needed Products in Civilian and Military Emergencies, United States。Emerging Infectious Diseases，13(7)，1046-1051。 | | 41. | Paek, Hye-Jin、Hilyard, Karen、Freimuth, Vicki S.、Barge, J. Kevin、Mindlin, Michele(2008)。Public support for government actions during a flu pandemic: Lessons learned from a statewide survey。Health Promotion Practice，9(4 Suppl.)，60S-72S。 | | 42. | Quinn, Sandra Crouse(2008)。Crisis and emergency risk communication in a pandemic: a model for building capacity and resilience of minority communities。Health Promotion Practice，9(4 Suppl)，18S-25S。 | | 43. | Quinn, Sandra Crouse、Jamison, Amelia M.、Freimuth, Vicki(2021)。Communicating Effectively about Emergency Use Authorization and Vaccines in the COVID-19 Pandemic。American Journal of Public Health，111(3)，355-358。 | | 44. | Quinn, Sandra Crouse、Kumar, Supriya、Freimuth, Vicki S.、Kidwell, Kelley、Musa, Donald(2009)。Public willingness to take a vaccine or drug under Emergency Use Authorization during the 2009 H1N1 pandemic。Biosecurity and Bioterrorism，7(3)，275-290。 | | 45. | Quinn, Sandra Crouse、Thomas, Tammy、Kumar, Supriya(2007)。The Anthrax Vaccine and Research: Reactions from Postal Workers and Public Health Professionals。Biosecurity & Bioterrorism，6(4)，321-333。 | | 46. | Reich, Daniel S.(2003)。Modernizing Local Responses to Public Health Emergencies: Bioterrorism, Epidemics, and the Model State Emergency Health Powers Act。Journal of Contemporary Health Law and Policy，19(2)，379-414。 | | 47. | Rizk, John G.、Forthal, Donald N.、Kalantar-Zadeh, Kamyar、Mehra, Mandeep R.、Lavie, Carl J.、Rizk, Youssef、Pfeiffer, JoAnn P.、Lewin, John C.(2020)。Expanded Access Programs, Compassionate Drug Use, and Emergency Use Authorizations During the COVID-19 Pandemic。Drug Discovery Today，26(2)，593-603。 | | 48. | Rubin, G. James、Amlȏt, Richard、Page, Lisa、Wessely, Simon(2009)。Public Perceptions, Anxiety, and Behaviour Change in Relation to the Swine Flu Outbreak: Cross Sectional Telephone Survey。British Medical Journal，339(b2651)。 | | 49. | Russell, Philip K.(2007)。Project BioShield: What It Is, Why It Is Needed, and Its Accomplishments So Far。Clinical Infectious Diseases，45(S1)，S68-S72。 | | 50. | Thomas, Stephen B.、Quinn, Sandra C.(1991)。The Tuskegee Syphilis Study, 1932 to 1972: Implications for HIV Education and AIDS Risk Education Programs in the Black Community。American Journal of Public Health，81(11)，1498-1505。 | | 51. | Winniford, Austin(2009)。Expanding Access to Investigational Drugs for Treatment Use: A Policy Analysis and Legislative Proposal。Health Matrix，19(1)，205-246。 | | 52. | Cassidy, Christine、Dever, Danielle、Stanbery, Laura、Edelman, Gerald、Dworkin, Lance、Nemunaitis, John(2020)。FDA Efficiency for Approval Process of COVID-19 Therapeutics。Infectious Agents and Cancer，15(1)，1-3。 | | 53. | Groopman, Jerome(20061210)。The Right to a Trial: Should Dying Patients Have Access to Experimental Drugs?。The New Yorker。 | | 54. | (20210602)。國產疫苗拿「緊急授權」標準太寬鬆？一文看懂高端、聯亞生技疫苗保護力、安全性關鍵重點。今周刊。 延伸查詢 | | 55. | Siegel, Marc(20041101)。Vaccine Poker。The Nation，2004(Nov.)。 | | 56. | Petts, Judith、Niemeyer, Simon(2004)。Health Risk Communication and Amplification: Learning from the MMR Vaccination Controversy。Health, Risk & Society，6(1)，7-23。 | 會議論文| 1. | (2010)。Medical Countermeasures Dispensing: Emergency Use Authorization and the Postal Model, Workshop Summary。Institute of Medicine (US) Forum on Medical and Public Health Preparedness for Catastrophic Events。 | 圖書| 1. | 何建志(2018)。公費疫苗法制解析與重構：科學不確定性下自主與公衛之平衡。元照。 延伸查詢 | | 2. | 林以璿(20210220)。COVID-19／AZ疫苗緊急授權通過！指揮中心回應來台施打時間。 延伸查詢 | | 3. | 疾病管制署(20210529)。我國疫苗政策兩大原則：由中央政府與原廠簽約採購並統籌分配執行。 延伸查詢 | 其他| 1. | 後疫情關鍵字：整合筆記編輯部(20210705)。COVID-19疫苗政策之法律爭議，https://covid19.nctu.edu.tw/article/10134。 延伸查詢 | | 2. | 中央社(20210803)。BNT疫苗新進度陳時中：下午簽核通過EUA，https://health.udn.com/health/story/121833/5647296。 延伸查詢 | | 3. | 王駿杰(20210607)。藥事法緊急授權法制不備 陽明交大團隊提修法草案建議，https://health.udn.com/health/story/120951/5514404。 延伸查詢 | | 4. | 行政院(20210712)。「三原則兩共識」公私協力達成BNT疫苗洽購 政院：確保疫苗穩定供應 保護國人健康，https://www.ey.gov.tw/Page/9277F759E41CCD91/f60cc186-52bd-491d-9e3f-21e90790fa9c。 延伸查詢 | | 5. | 何豪毅(20210512)。縣市政府可自購疫苗？陳時中點頭：符EUA合法合規即可，https://cnews.com.tw/174210512a02/。 延伸查詢 | | 6. | 吳亮儀(20210505)。莫德納疫苗通過食藥署緊急授權 陳時中：來台時程不變，https://news.ltn.com.tw/news/life/breakingnews/3521923。 延伸查詢 | | 7. | 吳亮儀(20210610)。嬌生疫苗通過我緊急使用授權 BNT僅「有條件通過」，https://news.ltn.com.tw/news/life/breakingnews/3565594。 延伸查詢 | | 8. | 吳亮儀(20210616)。國光、聯亞研發疫苗遭刁難？指揮中心嚴正澄清：標準一致，https://news.ltn.com.tw/news/life/breakingnews/3571712。 延伸查詢 | | 9. | 呂炯昌(20210527)。「疫苗有能力買到！」傅崑萁：政院速開放地方政府買疫苗，https://www.nownews.com/news/5279162。 延伸查詢 | | 10. | 李宗憲(20200122)。武漢肺炎：台灣首例確診者發病後搭機返鄉台叫停武漢雙向旅遊團，https://www.bbc.com/zhongwen/trad/chinese-news-51202545。 延伸查詢 | | 11. | 國家衛生研究院(20200410)。2020年國衛院論壇「台灣新冠肺炎COVID-19疫苗緊急開發策略」專家諮詢會議，https://enews.nhri.org.tw/archives/3381。 延伸查詢 | | 12. | 張茗喧，江慧珺(20210528)。地方政府、企業怎麼買疫苗？指揮中心公布流程，https://www.cna.com.tw/news/firstnews/202105280156.aspx。 延伸查詢 | | 13. | 張聰秋(20210525)。彰化重度熱區 王惠美盼開放企業買疫苗，https://news.ltn.com.tw/news/life/breakingnews/3545325。 延伸查詢 | | 14. | 陳奐宇，許政俊，孟昭權，溫嘉楷(20210621)。疑似注AZ死亡閣添17例 民眾注疫苗意願降低，https://news.pts.org.tw/article/531744。 延伸查詢 | | 15. | 陳郁仁，林炫均(20210618)。蔡政府授權台積電、鴻海 向BNT洽購1000萬劑疫苗，https://tw.news.yahoo.com/%E8%94%A1%E6%94%BF%E5%BA%9C%E6%8E%88%E6%AC%8A%E5%8F%B0%E7%A9%8D%E9%9B%BB-%E9%B4%BB%E6%B5%B7-%E5%90%91bnt%E6%B4%BD%E8%B3%BC1000%E8%90%AC%E5%8A%91%E7%96%AB%E8%8B%97-043904164.html。 | | 16. | 陳燕珩(20210624)。接種後死亡再添34例 莊人祥稱解剖26例「死因無關疫苗」，https://www.upmedia.mg/news_info.php?SerialNo=116804。 延伸查詢 | | 17. | 曾郡秋(20210610)。EUA標準為國產疫苗護航？食藥署駁：無關高端！是需取得國內AZ抗體數據，https://newtalk.tw/news/view/2021-06-10/587140。 延伸查詢 | | 18. | 葉韋辰(20210616)。獨厚高端？傳國光疫苗因基準不公遭淘汰 指揮中心說話了，https://news.tvbs.com.tw/life/1528941。 延伸查詢 | | 19. | 劉宏恩(20210827)。高端疫苗注射後死亡的因果關係如何認定？，https://forum.ettoday.net/news/2065873#ixzz7B7IMN5DL。 延伸查詢 | | 20. | 劉俊男(20210521)。捐疫苗須通過EUA食藥署：未收到申請，https://news.cts.com.tw/cts/society/202105/202105312044299.html。 延伸查詢 | | 21. | 衛生福利部中藥司(20210519)。衛生福利部核准「臺灣清冠一號濃縮製劑」專案製造，應經中醫師處方，民眾勿自行購買服用，https://www.mohw.gov.tw/cp-16-60830-1.html。 延伸查詢 | | 22. | 衛生福利部食品藥物管理署(2018)。公告第一階段適用藥害救濟法之藥物範圍，藥害救濟法令解釋彙集，https://www.tdrf.org.tw/wp-content/uploads/2019/01/201810-Drug-Injury-Relief-Act.pdf。 延伸查詢 | | 23. | 衛生福利部食品藥物管理署(20210501)。新型冠狀病毒檢驗試劑申請專案製造相關資訊，https://www.fda.gov.tw/TC/siteContent.aspx?sid=11671。 延伸查詢 | | 24. | 衛生福利部食品藥物管理署(20210610)。食藥署廣納並參考專家意見，訂定國產COVID-19疫苗緊急使用授權審查標準，透過嚴謹審查確保疫苗品質安全有效，https://www.mohw.gov.tw/cp-16-61305-1.html。 延伸查詢 | | 25. | 衛生福利部疾病管制署。嚴重特殊傳染性肺炎，https://www.cdc.gov.tw/Disease/SubIndex/N6XvFa1YP9CXYdB0kNSA9A。 延伸查詢 | | 26. | 韓婷婷(20210615)。高端公告 已向衛福部申請疫苗緊急使用授權，https://www.cna.com.tw/news/firstnews/202106150316.aspx。 延伸查詢 | | 27. | (20210325)。AZD1222 US Phase III primary analysis confirms safety and efficacy，https://www.astrazeneca.com/media-centre/press-releases/2021/azd1222-us-phase-iii-primary-analysis-confirms-safety-and-efficacy.html#!。 | | 28. | (20200401)。Coronavirus: Greatest test since World War Two, says UN chief，https://www.bbc.com/news/world-52114829。 | | 29. | U.S. Government Printing Office(2004)。BioShield II: Responding to an Ever-changing Threat : Joint Hearing Before the Committee on the Judiciary and Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Eighth Congress, Second Session, October 6, 2004，https://www.judiciary.senate.gov/meetings/bioshield-ii-responding-to-an-ever-changingthreat。 | | 30. | (20191121)。How Low Can They Go? Civil, Tort, Med Mal, Products Caseloads and Jury Trials，https://centerjd.org/content/how-low-can-they-go-civil-tort-med-mal-products-caseloads-and-jury-trials。 | | 31. | Kadlec, Robert(20130125)。Renewing the Project BioShield Act: What Has It Bought and Wrought?，https://www.cnas.org/publications/reports/renewing-the-project-bioshield-act-what-has-it-bought-and-wrought。 | | 32. | (20210823)。Pfizer-Biontech Covid-19 Vaccine Comirnaty® Receives Full U.S. FDA Approval for Individuals 16 Years and Older，https://www.pfizer.com/news/press-release/press-release-detail/pfizer-biontech-covid-19-vaccine-comirnatyr-receives-full。 | | 33. | Rapaport, Lisa(20150929)。U.S. 'Right to Try' Laws May Not Help Dying Get Unapproved Drugs，https://www.reuters.com/article/us-health-dying-experimental-drugs-idUSKCN0RS2LN20150928。 | | 34. | Ridwan, Raiiq(20200520)。Remdesivir and COVID-19: Justified in Emergency Use Authorization?，https://www.authorea.com/users/324516/articles/452684-remdesivir-and-covid-19-justified-in-emergency-use-authorization。 | | 35. | (20200813)。'This is the greatest public health crisis to hit this nation in a century': US CDC director，https://tbsnews.net/coronavirus-chronicle/greatest-publichealth-crisis-hit-nation-century-us-cdc-director-119023。 | | 36. | United States Department of Health and Human Services(20200131)。Determination that a Public Health Emergency Exists Nationwide as the Result of the 2019 Novel Coronavirus，https://www.phe.gov/emergency/news/healthactions/phe/Pages/2019-nCoV.aspx。 | | 37. | U.S. Food & Drug Admin。Emergency Use Authorization for Vaccines Explained，https://www.fda.gov/vaccines-blood-biologics/vaccines/emergency-use-authorization-vaccines-explained。 | | 38. | U.S. Food and Drug Administration(2017)。Emergency Use Authorization of Medical Products and Related Authorities，https://www.fda.gov/media/97321/download。 | | 39. | U.S. Food and Drug Administration。Expanded Access for Medical Devices，https://www.fda.gov/medical-devices/investigational-device-exemption-ide/expanded-access-medical-devices。 | | 40. | U.S. Food and Drug Administration(2017)。Expanded Access to Investigational Drugs for Treatment Use--Questions and Answers: Guidance for Industry，https://www.fda.gov/regulatory-information/search-fda-guidance-documents/expanded-access-investigational-drugs-treatment-use-questions-and-answers。 | | 41. | (20210823)。FDA Approves First COVID-19 Vaccine，https://www.fda.gov/news-events/press-announcements/fda-approves-first-covid-19-vaccine。 | | 42. | U.S. Food and Drug Administration(2017)。Format and Content of a REMS Document Guidance for Industry，https://www.fda.gov/media/77846/download。 | | 43. | U.S. Food and Drug Administration。Frequently Asked Questions (FAQs) about REMS，https://www.fda.gov/drugs/risk-evaluation-and-mitigation-strategies-rems/frequently-asked-questions-faqs-about-rems。 | | 44. | U.S. Food and Drug Administration。Risk Evaluation and Mitigation Strategies，https://www.fda.gov/drugs/drug-safety-and-availability/risk-evaluation-and-mitigation-strategies-rems。 | | 45. | Wamsley, Laurel(20201022)。Researchers Find Doubts About COVID-19 Vaccine Among People Of Color，https://www.npr.org/sections/coronavirus-live-updates/2020/10/22/926813331/researchersfind-doubts-about-covid-19-vaccineamong-people-of-color。 | | 46. | Werner, Michael J.，Klock, Sara M.。PREP Act: Liability Protection Is Available During COVID-19 Pandemic，https://www.hklaw.com/en/insights/publications/2020/05/prep-act-liability-protection-is-available-during-covid19-pandemic。 | | 47. | 吳亮賢(20210615)。又不公開會議記錄！時力批國產疫苗EUA審查標準黑箱，https://udn.com/news/story/122190/5533292。 延伸查詢 | | 48. | 侯俐安(20211019)。記者疫苗嚴重不良反應認定模糊 陳時中允一個月修正，https://udn.com/news/story/122190/5827185。 延伸查詢 | | 49. | (20210624)。打疫苗169人逝 台中市增4例共34死最多！台北增8例共17死，https://tw.appledaily.com/life/20210624/6LPFJOPW6REC5PFL4DXLRE42ME/。 延伸查詢 | | 50. | 張君堯(20190616)。美新研究：新冠病毒早在2019年12月中就在美國出現，https://udn.com/news/story/121707/5535356。 延伸查詢 | | 51. | 郭政芬，陳雨鑫，邱宜君(20200414)。快篩難行卡在3關鍵，https://udn.com/news/story/120940/4489781。 延伸查詢 | | 52. | 陳雨鑫(20200529)。台灣新冠試劑研發錯過最佳時機 專家提三點補救方案，https://udn.com/news/story/120940/4599823。 延伸查詢 | | 53. | 陳惠玲(20210624)。AZ疫苗接種意願低 汐止75歲施打率剩2成5，https://udn.com/news/story/7323/5555721。 延伸查詢 | | 54. | 陳熙文(20210618)。不只授權郭台銘 政院宣布台積電、永齡代表政府洽購1000萬劑疫苗，https://udn.com/news/story/122190/5541215。 延伸查詢 | | 55. | 楊喻斐，林巧雁(20210615)。郭台銘買疫苗露曙光永齡已接獲有條件專案進口許可函，https://tw.appledaily.com/property/20210615/MH66XF64FRHT5DPYGOQ6FVFFWA/。 延伸查詢 | | 56. | 鍾兆馨(20210624)。疫苗後死亡 速設EUA藥害補償基金，https://udn.com/news/story/7339/5553693。 延伸查詢 | | 57. | 蘇南(20210620)。接種後死亡誰該負責？如何求償？新冠疫苗的法律風險，https://tw.appledaily.com/forum/20210620/JPPGHXT64BHQJPE3MYBILJUXTY/。 延伸查詢 | 圖書論文| 1. | Quinn, Sandra Crouse、Thomas, Tammy、McAllister, Carol(2008)。Lessons from the 2001 Anthrax Attack: A Conceptual Model for Crisis and Emergency Risk Communication。Crisis Communication And The Public Health。 | |